IBIO supply chain intelligence for iBio, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
iBio, Inc. (IBIO) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| RUBRYC | RUBRYC | 92% | iBio also entered into a Stock Purchase Agreement with RubrYc whereby we purchased 1,909,563 shares of RubrYc's Series A-2 preferred stock |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc., Terns Pharmaceuticals, Inc., Skye Bioscience, Inc., SixPeaks Bio AG, Laekna, Inc… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ALNY graph: Reciprocal relationship from IBIO graph: Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc.… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ARWR graph: Reciprocal relationship from IBIO graph: Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc.… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc., Terns Pharmaceuticals, Inc., Skye Bioscience, Inc., SixPeaks Bio AG, Laekna, Inc… |
| BMY | Bristol-Myers Squibb Company | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from IBIO graph: t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candida… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from BMYM… |
| CLDX | Celldex Therapeutics, Inc. | 72% | Reciprocal relationship from CLDX graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from CLDX g… |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from GILD graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from GILD g… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from JNJ grap… |
| KROS | Keros Therapeutics, Inc. | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| KROS | Keros Therapeutics, Inc. | 72% | Reciprocal relationship from KROS graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from KROS graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from KROS g… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from LLY graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from LLY grap… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from MRK graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from MRK grap… |
| SKYE | Skye Bioscience, Inc. | 72% | Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc., Terns Pharmaceuticals, Inc., Skye Bioscience, Inc., SixPeaks Bio AG, Laekna, Inc… |
| SKYE | Skye Bioscience, Inc. | 72% | Reciprocal relationship from SKYE graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from SKYE graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from SKYE g… |
| TERN | Terns Pharmaceuticals, Inc. | 72% | Reciprocal relationship from TERN graph: Reciprocal relationship from IBIO graph: Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc.… |
| TERN | Terns Pharmaceuticals, Inc. | 72% | Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc., Terns Pharmaceuticals, Inc., Skye Bioscience, Inc., SixPeaks Bio AG, Laekna, Inc… |
| TWST | Twist Bioscience Corporation | 72% | Reciprocal relationship from TWST graph: Reciprocal relationship from IBIO graph: as well as enhancements to our existing offerings, both of which are necessary to maintain our competitive position. … |
| TWST | Twist Bioscience Corporation | 72% | as well as enhancements to our existing offerings, both of which are necessary to maintain our competitive position. Our research and development activities take place primarily at our facilities in … |
| VKTX | Viking Therapeutics, Inc. | 72% | Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc., Terns Pharmaceuticals, Inc., Skye Bioscience, Inc., SixPeaks Bio AG, Laekna, Inc… |
| VKTX | Viking Therapeutics, Inc. | 72% | Reciprocal relationship from VKTX graph: Reciprocal relationship from IBIO graph: Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc.… |
| WVE | Wave Life Sciences Ltd. | 72% | Reciprocal relationship from WVE graph: Reciprocal relationship from IBIO graph: Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc.,… |
| WVE | Wave Life Sciences Ltd. | 72% | Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc., Terns Pharmaceuticals, Inc., Skye Bioscience, Inc., SixPeaks Bio AG, Laekna, Inc… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ALNY graph: Reciprocal relationship from IBIO graph: t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candid… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ARWR graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from ARWR g… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from IBIO graph: t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candida… |
| BMY | Bristol-Myers Squibb Company | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from BMYM… |
| BMYMP | Bristol-Myers Squibb Co | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| CLDX | Celldex Therapeutics, Inc. | 72% | Reciprocal relationship from CLDX graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from CLDX g… |
| CLDX | Celldex Therapeutics, Inc. | 72% | icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources be… |
| GILD | Gilead Sciences, Inc. | 72% | icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources be… |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from GILD graph: Reciprocal relationship from IBIO graph: icantly more experience commerciali… |
| JNJ | Johnson & Johnson | 72% | icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources be… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from IBIO graph: icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the p… |
| KROS | Keros Therapeutics, Inc. | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| KROS | Keros Therapeutics, Inc. | 72% | Reciprocal relationship from KROS graph: Reciprocal relationship from IBIO graph: t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candid… |
| LLY | Eli Lilly and Company | 72% | icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources be… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from IBIO graph: icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the p… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from MRK graph: Reciprocal relationship from IBIO graph: icantly more experience commercializi… |
| MRK | Merck & Co., Inc. | 72% | icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources be… |
| TERN | Terns Pharmaceuticals, Inc. | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| TERN | Terns Pharmaceuticals, Inc. | 72% | Reciprocal relationship from TERN graph: Reciprocal relationship from IBIO graph: t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candid… |
| TWST | Twist Bioscience Corporation | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| TWST | Twist Bioscience Corporation | 72% | Reciprocal relationship from TWST graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from TWST graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from TWST g… |
| VKTX | Viking Therapeutics, Inc. | 72% | t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. There are currently approved vaccines and the… |
| VKTX | Viking Therapeutics, Inc. | 72% | Reciprocal relationship from VKTX graph: Reciprocal relationship from IBIO graph: t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candid… |
| WVE | Wave Life Sciences Ltd. | 72% | Reciprocal relationship from WVE graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from WVE graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from WVE grap… |
| BRYAN-CAPITAL-INVESTORS-LLC | BRYAN-CAPITAL-INVESTORS-LLC | 62% | eration of the payment in full of all Obligations (as such term is defined under the Credit Agreement (a) we paid to Woodforest (i) $8,500,000, which it received from the sale of the Property under t… |
| CDMO-LLC | CDMO-LLC | 62% | pany does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the years ended June 30, 2024 and 2023. Conc… |
| CHARDAN-CAPITAL-MARKETS-LLC | CHARDAN-CAPITAL-MARKETS-LLC | 62% | range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, obtaining regulatory approval for these product candidates and manufacturing, … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| IBIO-DEBT-10165 | Warrants outstanding: 9595002 | 90% | xbrl warrant detail from xbrl 2024-06-30. |
| IBIO-DEBT-10166 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2024-06-30. |
| IBIO-DEBT | Debt stack $2.3M | 90% | Market cache reports total debt of $2.3M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| IBIO-OWNER-AFFINITY-ASSET-ADVISORS-LLC | Affinity Asset Advisors, LLC | 90% | 13F overlay lists Affinity Asset Advisors, LLC as top holder; 53 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| BNRG | Brenmiller Energy Ltd | 100.00 | 2 | |
| IMMP | Immutep Limited | 100.00 | 2 | |
| FHTX | Foghorn Therapeutics Inc. | 100.00 | 2 | |
| GRAL | GRAIL, Inc. | 100.00 | 2 | |
| BNR | Burning Rock Biotech Limited | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| AVIR | Atea Pharmaceuticals, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 |